We're thrilled to announce our participation at H.C. Wainwright & Co., LLC's 8th Annual MASH Virtual Conference next week! Did you know MASH is the second leading cause of liver transplant among all adults? At 89bio, we recognize the prevalence and severity of MASH and therefore we are committed to delivering innovative therapies for the treatment of liver diseases. For more information about our attendance, read our release: https://lnkd.in/grXgHmFp #Biotech #StartUp #MASH #Innovation
89bio
Biotechnology Research
San Francisco, CA 10,902 followers
Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases
About us
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
- Website
-
http://www.89bio.com
External link for 89bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Public Company
- Founded
- 2018
- Specialties
- Biopharmaceutical
Locations
-
Primary
San Francisco, CA, US
Employees at 89bio
Updates
-
Earlier this week, our CEO Rohan Palekar traveled to Boston to attend the World Medical Innovation Forum. Rohan shared his insights and expertise on “The Innovation Gap: The Broader Impact of Metabolic Drugs on Related Diseases” panel. Thank you, Rohan for driving our mission forward to expand treatment options for cardiometabolic diseases. Learn more about our work here: https://lnkd.in/grqTsDmY #Biotech #StartUp #MASH #Innovation
-
Our team is growing! At 89bio, we strive to build a team of hardworking and passionate visionists driven to deliver therapeutics for #cardiometabolic diseases. Consider joining our team. Check out our website to learn more about our current job openings: https://lnkd.in/gnP5i8-n #Lifeat89bio #the89Way #BioPharma #Recruitment #JobOpening #NewJobs
-
Our team is excited to announce the appointment of Teresa Perney as Chief Regulatory and Quality Officer. Dr. Perney brings over 20 years of experience to 89bio and will serve a crucial role in bringing our therapeutics to patients. To learn more, visit our website to read the full release: https://lnkd.in/gF29D3QH #LiverDisease #MASH #SHTG #Team89bio
-
Metabolic dysfunction-associated steatohepatitis, or MASH, is often referred to as a silent disease. This is because it advances quietly, often without symptoms, and can lead to severe complications like cirrhosis and liver cancer if left to progress. The primary goal in treating MASH is to reduce fibrosis of the liver, which can be a major predictor of poor clinical outcomes, such as cirrhosis. At 89bio, we're committed to developing innovative therapies for the treatment MASH with advanced fibrosis. Learn more here: https://lnkd.in/gsWwps_X #CardioMetabolicDiseases #Innovation #MASH
-
This week, our team will head to the Gastroenterology & Hepatology Advanced Practice Providers Conference to present data from our Phase 2 ENLIVEN study. Currently, around 27 million people in the U.S. have MASH, and estimates suggest that approximately 20% of patients may develop cirrhosis, a severe complication that significantly impairs liver function. It's clear there is an urgent need for treatments for those with advanced MASH - and 89bio is hoping to answer the call with our lead FGF21 therapeutic candidate. Learn more about our science: https://lnkd.in/guaY8Zz #GHAPP2024 #MASH #Innovation #Hepatology #Gastroenterology
-
We're thrilled to announce our participation in three prestigious upcoming healthcare investor conferences. It's an exciting time as we share our progress and connect with other leaders in the industry. Here's where you can find us: 📍Wells Fargo Healthcare Conference in Boston on September 5th at 12:45 pm ET. 📍HC Wainwright in New York on September 9th at 11:30 am ET. 📍Cantor Fitzgerald in New York on September 17th at 11:30 am ET. We look forward to sharing the progress on our clinical development programs. Stay tuned for updates and breakthroughs from #Team89bio! Learn more: https://lnkd.in/gH_q5Ki9 #Biotech #StartUp #Innovation #MASH #SHTG
-
Severe hypertriglyceridemia (#SHTG) is a condition where triglyceride levels exceed 500 mg/dL and it can pose serious health risks, including acute #pancreatitis, which is a painful and potentially dangerous inflammation of the pancreas. SHTG is a primary focus area at 89bio. Learn more about the condition and how we are addressing this #CardioMetabolic disease: https://lnkd.in/gE7AwYWu #HeartHealth #Innovation
-
We are thrilled to announce the appointment of Francis Sarena as 89bio’s Chief Operating Officer. With over 25 years of experience, Mr. Sarena brings extensive leadership, strategic, and operational expertise to our growing team. Mr. Sarena will be a valuable asset as we advance our Phase 3 clinical program of our FGF21 analog for the treatment of #MASH and #SHTG. To learn more about Mr. Sarena and this exciting addition to our leadership team, visit: https://lnkd.in/gUAjBNME
-
Today, 89bio reported their Q2 2024 financial earnings and business update. We're thrilled to share our latest achievements and milestones – and would like to extend an extra thank you for all our incredible team’s hard work and dedication; we've seen remarkable progress and growth this quarter. Read our release to learn more: https://lnkd.in/gCCJavti